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Summary
 
It remains controversial whether human T lymphotropic virus type I (HTLV-I) coinfection
leads to more rapid progression of human immunodeficiency virus (HIV) disease in dually in-
fected individuals. To investigate whether HTLV-I infection of certain cells can modulate
HIV-1 infection of surrounding cells, primary CD4
 
1
 
 T cells were treated with cell-free super-
natants from HTLV-I–infected MT-2 cell cultures. The primary CD4
 
1
 
 T cells became resis-
tant to macrophage (M)-tropic HIV-1 but highly susceptible to T cell (T)-tropic HIV-1. The
CC chemokines RANTES (regulated on activation, normal T cell expressed and secreted),
macrophage inflammatory protein (MIP)-1
 
a
 
, and MIP-1
 
b
 
 in the MT-2 cell supernatants were
identified as the major suppressive factors for M-tropic HIV-1 as well as the enhancers of
T-tropic HIV-1 infection, whereas soluble Tax protein increased susceptibility to both M- and
T-tropic HIV-1. The effect of Tax or CC chemokines on T-tropic HIV-1 was mediated, at
least in part, by increasing HIV Env-mediated fusogenicity. Our data suggest that the net effect
of HTLV-I coinfection in HIV-infected individuals favors the transition from M- to T-tropic
HIV phenotype, which is generally indicative of progressive HIV disease.
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D
 
uring the natural course of human immunodeficiency
virus (HIV) infection, a transition of HIV phenotypes
has been observed (1–3). During primary infection and the
clinically latent period, most HIV isolates are macrophage
(M)-tropic (4), whereas in the advanced stage of HIV dis-
ease more cytopathic, T cell (T)-tropic viruses predominate
(1–3). However, the host or environmental factors affecting
such a transition and the reason why HIV disease progresses
more rapidly in certain individuals remain unclear.
The effects of coinfection with other pathogens on the
pathogenesis of HIV-1 disease have been extensively stud-
ied over the past decade. For example, a number of viral
transactivators have been shown to upregulate expression
from the HIV-1 LTR (5–8), and more recently, a human
cytomegalovirus (HCMV)
 
1
 
–encoded chemokine receptor
was found to serve as an HIV-1 entry cofactor (9). Al-
though these in vitro studies provide important mechanistic
information, the effects mediated by those pathogens re-
quired coinfection of the pathogens and HIV-1 in the same
cell, a phenomenon that is considered to occur rarely in
vivo.
Several laboratory and epidemiologic studies have sug-
gested that human T lymphotropic virus type I (HTLV-I)
infection exacerbates the cytopathic effects of HIV infec-
tion and accelerates the clinical progression of HIV disease
in coinfected individuals (10–16); however, other studies
have not confirmed these observations (17). To determine
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the potential mechanisms whereby HTLV-I infection
might modulate HIV-1 infection in dually infected indi-
viduals, we used in vitro
 
 
 
models consisting of primary
CD4
 
1
 
 T cells either cocultured with HTLV-I–transformed
MT-2 cells in a transwell system or incubated in the pres-
ence of cell-free supernatants from MT-2 cell cultures. We
demonstrate that crude supernatants from MT-2 cell cul-
tures inhibit replication of M-tropic HIV-1, but enhance
that of T- or dual-tropic HIV-1. In addition, the CC
chemokines RANTES (regulated on activation normal T
cell expressed and secreted), macrophage inflammatory pro-
tein (MIP)–1
 
a
 
, and MIP-1
 
b
 
 in the supernatants of the MT-2
cell cultures were identified as the major suppressive factors
for M-tropic HIV-1 as well as the positively regulating factors
for T-tropic HIV-1. Furthermore, soluble Tax protein was
shown to be a positively regulating factor for both HIV-1
phenotypes. The effect of Tax or CC chemokines is medi-
ated, at least in part, by enhancing HIV-1 Env-mediated fuso-
genic activity. This study suggests that HTLV-I coinfection
in HIV-infected individuals may facilitate transition from
an M- to a T-tropic HIV phenotype, which is generally in-
dicative of progression to an advanced stage of HIV disease.
 
Materials and Methods
 
Cells.
 
HTLV-I–transformed MT-2 (18) and HUT-102 (19) cells
were provided by G. Franchini (National Cancer Institute, NIH, Be-
thesda, MD) and grown in RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS; GIBCO BRL, Gaithersburg, MD).
JPX9 cells and JPX/M cells are Jurkat cells expressing the wild-
type or mutant form, respectively, of HTLV-I Tax under the control
of the metallothionein promoter (20, 21). Expression of Tax in these
cells was induced by treatment of cells with 10 
 
m
 
M CdCl
 
2
 
 for 2 d.
PBMCs were isolated from healthy volunteers seronegative for
both HIV and HTLV, as previously described (22), and CD4
 
1
 
 
 
T
cells were negatively selected by column exclusion (CD4
 
1
 
 subset
enrichment columns; R&D Systems, Minneapolis, MN). Purity
of CD4
 
1
 
 T cells was 95% or more, determined by flow cytomet-
ric analysis (data not shown).
 
Propagation of MT-2–conditioned Medium.
 
Crude supernatants
from MT-2 cell cultures were clarified by low-speed centrifuga-
tion (3,000 rpm, 30 min) and filtered through 0.2-
 
m
 
m filters to
remove cells. The medium (5 ml/aliquot) was incubated with ei-
ther control rabbit serum (20 
 
m
 
l), anti-Tax antiserum (20 
 
m
 
l [ref-
erence 23]), or a mixture of monoclonal antibodies to RANTES,
MIP-1
 
a
 
, and MIP-1
 
b
 
 (50 
 
m
 
g/ml each; R&D Systems) at 4
 
8
 
C for
2 h, followed by protein A/G sepharose (UltraLink Immobilized
Protein A/G; Pierce, Rockford, IL). Immune complexes bound
on the sepharose were removed by extensive washing. The pres-
ence of soluble Tax protein in the medium was demonstrated by
immunoprecipitation using anti-Tax serum and protein A/G
sepharose, and the concentrations of CC chemokines in the me-
dium were determined by ELISAs using commercially available
kits (R&D Systems). Where indicated, the supernatants were ul-
tracentrifuged at 20,000 rpm for 1 h to pellet HTLV-I virions.
Crude supernatants from HUT-102 or A3.01 cells were also
propagated in a similar manner.
 
Purification of Recombinant Tax Protein Expressed in Escherichia coli
DH5a Strain and HTLV-I Particles from MT-2 Cells.
 
Tax protein
was expressed in 
 
E. coli 
 
DH5a strain transformed with pGST-Tax
(provided by K.T. Jeang, National Institute of Allergy and Infectious
Diseases, NIH, Bethesda, MD), and purified as previously described
(24). As a control, glutathione S-transferase (GST) protein was
also expressed and purified in the same manner. Both prepara-
tions were dialyzed and filtered, and protein concentrations were
measured by colorimetric assays (Bio-Rad Laboratories, Hercules,
CA). Levels of contaminated endotoxin in the preparations were
 
,
 
10 ng/mg protein (Limulus Amebocyte Lysate Test; BioWhit-
taker, Inc., Walkersville, MD). Purity and identity of the proteins
were determined by SDS-PAGE followed by Coomassie blue
staining and Western blotting using anti-Tax antiserum (1:2,000),
respectively. In some experiments, the GST-Tax preparation was
treated by anti-Tax serum followed by protein A/G sepharose to
specifically remove GST–Tax fusion protein. Nuclear extracts
were prepared from CD4
 
1
 
 T cells treated with either GST or
GST-Tax as previously described (24), and were analyzed by
Western blotting to monitor cellular uptake of the protein.
HTLV-I particles were purified from MT-2 cell culture super-
natants as previously described (25).
 
Virus Strains and Infection.
 
The following virus stocks were
propagated by transfecting 293T cells with plasmids encoding the
respective molecular clones: NL4-3 (T-tropic [reference 26]); 89.6
(dual-tropic [reference 27]); and ADA8 (M-tropic [reference 28]).
Approximately 2
 
 3 
 
10
 
5
 
 CD4
 
1
 
 T cells were either pretreated with
50% MT-2–conditioned medium or control medium (A3.01-con-
ditioned medium) or cocultured with MT-2 cells in a transwell
system that separates the two cell populations by 0.2-
 
m
 
m pore
membrane for 3 d, and then infected with the above molecular clone
stock at a multiplicity of infection (MOI) of 
 
z
 
0.05. Approximately
half of each infected cell culture supernatant was replaced with
the same medium every 4 d, and reverse transcriptase (RT) activ-
ity in the supernatants was measured as previously described (29).
 
Single-round Virus Replication Assay.
 
NL4-3-Luc-R
 
2
 
E
 
2
 
 virus
stocks pseudotyped by various Envs were generated by transfect-
ing 293T cells with pNL4-3-Luc-R
 
2
 
E
 
2
 
 and plasmids expressing
Env from either HXB2 (T-tropic), 89.6 (dual-tropic [reference
30]), ADA (M-tropic [reference 30]) or amphotropic murine leu-
kemia virus (AMV), as previously described (31). Approximately
10
 
5
 
 primary CD4
 
1
 
 T cells were infected with the above luciferase
reporter virus (5 
 
3 
 
10
 
5
 
 cpm RT activity), and luciferase activity
of the cell lysates was measured 4 d after infection using commer-
cially available reagents (Promega, Madison, WI).
 
Fusion Assay.
 
Recombinant vaccinia virus (rVV)-based cell
fusion assays were performed as previously described (32, 33). In
brief, primary CD4
 
1
 
 T cells (fusion targets) were infected with
vTF7-3 (expressing T7 RNA polymerase) at an MOI of 10; as
fusion effectors, BSC-1 cells or CD4
 
1
 
 
 
T cells were infected with
vCB21R (encoding the 
 
lacZ
 
 gene driven by the T7 promoter) as
well as rVV expressing the mutant HIV Env (vCB16), wild-type
IIIB (T-tropic) Env (vCB41), or Ba-L (M-tropic) Env (vCB43),
each at an MOI of 10. Cells were incubated at 31
 
8
 
C overnight,
and both fusion targets and fusion effectors were mixed per well
in 96-well flat-bottomed microtiter plates in the presence of 40
 
m
 
g/ml of cytosine arabinoside. After 4 h at 37
 
8
 
C, 
 
b
 
-galactosidase
activity in the cell lysates were assayed by measuring absorbance
at 570 nm using a microtiter absorbance reader (Molecular Dy-
namics, Sunnyvale, CA).
 
Results and Discussion
 
HTLV-I–transformed MT-2 Cells Produce Soluble Factor(s)
that Inhibits Infection of Primary CD4
 
1
 
T Cells with M-tropic
HIV-1 and that Enhance Replication of T-tropic HIV-1.
 
The ability of HTLV-I to modulate HIV-1 infection with- 
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out coinfection of the same cell was initially evaluated by
coculturing primary CD4
 
1
 
 T cells with MT-2 cells in a
transwell system for 3 d before HIV-1 infection. In this sys-
tem, the two cell populations were separated by a 0.2-
 
m
 
m
pore membrane to avoid cell-to-cell contact, which is re-
quired for the establishment of infection with highly cell-
associated HTLV-I (34–36). Under these conditions, im-
mortalization of CD4
 
1
 
 T cells did not occur and HTLV-I
p24 antigen was not detected in the CD4
 
1
 
 T cell culture
supernatants over 3 wk (data not shown). Primary CD4
 
1
 
 T
cells pretreated in the MT-2 cell coculture system de-
scribed above were then infected with either M-tropic
HIV-1
 
ADA
 
 or T-tropic HIV-1
 
NL4-3
 
, and RT activity was
measured in the infected cell supernatants. CD4
 
1
 
 T cells
cocultured with MT-2 cells before infection produced less
HIV-1
 
ADA
 
 but more HIV-1
 
NL4-3
 
 compared with control
CD4
 
1
 
 T cells on day 4 after infection (Fig. 1, 
 
A
 
 and 
 
B
 
);
however, these effects were not observed beyond 8 d after
infection.
The above results suggested that MT-2–conditioned
medium contains soluble factor(s) that suppress M-tropic
but enhance T-tropic HIV-1 infection; however, neither
the positive nor the negative effects persisted beyond a few
days after exposure to the supernatants. To provide contin-
uous exposure of CD4
 
1
 
 T cells to the putative factors,
crude cell-free supernatants were prepared from MT-2 cell
cultures. Primary CD4
 
1
 
 T cells were pretreated for 3 d and
then continuously exposed to a 1:1 dilution of the superna-
tants after infection with T-tropic HIV-1
 
NL4-3
 
, dual-tropic
HIV-1
 
89.6
 
, or M-tropic HIV-1
 
ADA
 
. In this setting, the en-
hancing effects of the supernatant on T-tropic and dual-tropic
HIV-1 infection and the suppressive effects on M-tropic
HIV-1 infection were sustained throughout the 12-d culture
period (Fig. 2, 
 
A
 
–
 
C
 
).
The effect by continuous treatment with MT-2–condi-
tioned medium on HIV-1 infection of primary CD4
 
1
 
 T
cells was also investigated in single-round virus replication
assays. In this system, the input virus is pseudotyped by
Envs of interest and expresses the luciferase gene after inte-
gration of proviral DNA into the host genome; however, it
is unable to complete its life cycle because of the lack of de
novo
 
 
 
Env production. Therefore, luciferase activity in the
infected cell lysates correlates well with the efficiency of vi-
rus replication during early events in the viral replicative
cycle. As expected, coculture with MT-2 cells in a trans-
well system before infection (data not shown) or pretreat-
ment with MT-2–conditioned medium (Fig. 3) reduced
infectivity of virus pseudotyped by M-tropic Env but in-
creased infectivity of virus pseudotyped by T-tropic HIV-1
Env, suggesting that the steps during the HIV-1 replicative
cycle that are influenced by HTLV-I coinfection include
early events. Similar results were obtained by using crude
Figure 1. M-tropic HIV-1 infection is downregulated and T-tropic
HIV-1 infection is enhanced in primary CD41 T cells cocultured with
HTLV-I–infected MT-2 cells in a transwell system. Primary CD41 T
cells isolated from HIV/HTLV seronegative individuals either were un-
treated or were cocultured with MT-2 cells in a transwell (0.2-mm pore
membrane) culture for 3 d, and infected with either HIV-1NL4-3 (A) or
HIV-1ADA (B). Cell-free supernatants were collected on days 4, 8, and 12
after infection and assayed for RT activity. Experiments were repeated
twice with similar results.
Figure 2. M-tropic HIV-1 in-
fection is downregulated and
T-tropic HIV-1 infection is en-
hanced over a 12-d culture pe-
riod in primary CD41 T cells
treated continuously with MT-2
cell culture supernatants. Primary
CD41 T cells were pretreated
with cell-free crude supernatants
from either A3.01 cells (control)
or MT-2 cells (MT-2 sup) at a 1:
1 ratio for 3 d before infection
with HIV-1NL4-3 ( A ), HIV-189.6
(B), or HIV-1ADA ( C ). Culture
medium was replaced with the
same medium containing either
control or MT-2 cell supernatant
every 4 d after infection, and RT
activity was measured. Repre-
sentative results from three inde-
pendent experiments are shown. 
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supernatants from another HTLV-I producing cell line,
HUT-102 (data not shown).
 
Identification of Negative and Positive Factors Produced by
MT-2 Cells.
 
MT-2 cells are known to produce HTLV-I
virions, viral proteins such as Tax (37–39), and a number of
cytokines (for review see reference 40). Of note, HTLV-
I–transformed CD8
 
1
 
 T cells were recently shown to produce
the CC chemokines RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
, and
to suppress infection of a CD4
 
1
 
 T cell line with M-tropic
HIV-1 (41). In contrast, previous studies had demonstrated
that mitogenic stimulation induced by HTLV-I virions in-
creased HIV-1 replication (25), and that HTLV-I Tax pro-
tein transactivated HIV-1 LTR (8) as well as induced ex-
pression of several cytokines including CC chemokines
(42). Therefore, it is likely that the net effect of crude su-
pernatants from HTLV-I–infected cells on HIV-1 infection
of adjacent cells depends upon the balance and/or accumu-
lation of these factors. To clarify which factor(s) is responsi-
ble for the positive or negative effects on HIV-1 infection,
each component (soluble Tax protein, HIV-suppressive
CC chemokines, or HTLV-I virions) was removed from
the crude supernatants as described in Materials and Meth-
ods. Fig. 4 
 
A
 
 demonstrates that MT-2 cell supernatants
contain soluble Tax protein (lane 
 
2
 
), which was success-
fully removed by anti-Tax antiserum followed by protein
A/G sepharose treatment (lane 
 
4
 
). MT-2 cell supernatants
also contain substantial amounts of the CC chemokines
RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
, which were markedly
reduced after treatment with specific antibodies and protein
A/G sepharose (Fig. 4 
 
B
 
).
CD4
 
1
 
 T cells were treated with these supernatant prepa-
rations and infected with NL4-3Luc-R
 
2
 
E
 
2
 
 virus pseudo-
typed by Env from either HIV-1
 
HXB2
 
 (T-tropic), HIV-1
 
89.6
 
(dual-tropic), or HIV-1
 
ADA
 
 (M-tropic). Supernatants sub-
tracted for the CC chemokines RANTES, MIP-1
 
a
 
, and
MIP-1b lost their inhibitory effects on M-tropic HIV-1,
and instead enhanced its replication, whereas supernatants
subtracted for either Tax or HTLV-I virions retained or
further augmented their inhibitory activity. In contrast,
subtraction of either component (Tax, CC chemokines, or
virions) reduced the ability of the supernatants to increase
replication of T- (Fig. 4 C) or dual-tropic (data not shown)
HIV-1. These results indicate that both soluble Tax protein
and HTLV-I virions enhance HIV-1 infection of both
M-tropic and T-tropic viral phenotypes, whereas the CC
chemokines in the supernatants inhibit M-tropic HIV-1 in-
fection and enhance infection with T-tropic HIV-1 infec-
tion. Therefore, supernatants from HTLV-I–infected cells
invariably enhance infection with T-tropic HIV-1, since
each of the identifiable factors in the supernatants (Tax, CC
chemokines, and HTLV-I virions) have a positive effect on
replication of viruses of these phenotypes. However, al-
though the effect of the crude supernatant on M-tropic
Figure 3. Soluble factors pro-
duced by MT-2 cells modulate
early events in the HIV-1 repli-
cation cycle. Primary CD41 T
cells were pretreated with cell-
free crude supernatants from ei-
ther A3.01 cells (control) or MT-2
cells (MT-2 sup) at a 1:1 ratio for
3 d before infection with NL4-
3-Luc-R2E2 virus pseudotyped
by Env from HIV-1HXB2, HIV-
189.6, or HIV-1ADA. Luciferase
activity in the infected cell lysates
was measured on day 4 after in-
fection. Representative results
from three independent experi-
ments are shown.
Figure 4. HTLV-I transactiva-
tor Tax protein and the CC
chemokines RANTES, MIP-1a,
and MIP-1b produced by MT-2
cells modulate HIV-1 infection.
(A) MT-2 cells produce and se-
crete a soluble form of HTLV-I
transactivator Tax protein. Crude
supernatants from A3.01 cells (con-
trol; lane 1) or MT-2 cell superna-
tants treated with control serum
(MT-2 sup; lane 2), mAbs to
RANTES, MIP-1a, and MIP1b
(2CC chemokines; lane 3), or anti-
Tax antiserum (-Tax; lane 4) fol-
lowed by protein A/G sepharose
were immunoprecipitated with
anti-Tax antiserum and protein A/G
sepharose, subjected to 10% SDS-
PAGE, and transferred to nitrocel-
lulose membrane for Western
blotting. The blot was probed with anti-Tax antiserum and horseradish peroxidase–conjugated protein A (Amersham Corp., Arlington Heights, IL). (B)
MT-2 cells produce and secrete CC chemokines. Concentrations of RANTES, MIP-1a, and MIP-1b in the above supernatants were measured with
ELISA. (C) The effect of subtraction of each component from MT-2 cell supernatants on HIV-1 infection. Primary CD41 T cells were treated with the
indicated supernatants at a 1:1 ratio for 3 d before infection with HIV-1NL4-3 or HIV-1ADA. Culture medium was replaced with the same medium every 4 d
after infection, and RT activity was measured. Peak RT activities on day 12 are shown. Experiments were repeated three times with similar results.1693 Moriuchi et al.
HIV-1 infection in the experiments shown (Figs. 1 B, 2 C,
3, and 4 C) were inhibitory, the net effect depends on the
balance of enhancing and suppressing factors as demon-
strated by the subtraction experiments in which individual
components of the crude supernatant were removed (Fig. 4
C). In fact, when comparing different donors as sources of
CD41 T cells, we have consistently noted marked en-
hancement of T-tropic HIV-1 infection. In contrast, the
degree of inhibition of M-tropic HIV-1 infection varied
greatly among donors, suggesting differences in susceptibil-
ity among the donors to the net balance of enhancing and
inhibitory factors contained in the MT-2 supernatants.
Soluble Tax Protein Increases Fusogenicity of CD41 T Cells
with Envs from HIV-1. The role of HTLV-I Tax protein
in HIV-1 infection of CD41 T cells was further investi-
gated in two different systems. First, we purified Tax pro-
tein from E. coli transformed with a GST–Tax fusion pro-
tein expression vector (Fig. 5 A). When added to CD41 T
cell cultures, the GST–Tax protein was taken up by the
cells and transferred to the nucleus (Fig. 5 B). The effect of
Tax protein on HIV-1 infection was tested and compared
with that of TCR signaling induced by anti-CD3 antibody.
It can be postulated from previous studies that HTLV-
I–infected T cells can secrete Tax protein in the concentra-
tion (20 ng/ml) used in this study, which is sufficient to
produce biological activities such as cytokine production
(37–39). Stimulation of CD41 T cells with purified Tax
protein alone or anti-CD3 mAb alone minimally enhanced
Figure 5. Purified Tax protein, in combination with anti-CD3 antibody, increases susceptibility to fusogenicity with Env from HIV-1. (A) GST–Tax
fusion protein was purified as described in the Materials and Methods, subjected to 10% SDS-PAGE (lane 2), and transferred to nitrocellulose membrane
for Western blotting, and then the blot was probed with anti-Tax antiserum and horseradish peroxidase–conjugated protein A. GST protein was prepared
in the same manner and used as a control (lane 1). (B) GST–Tax fusion protein was taken up by the cells and transferred to the nucleus. Nuclear extracts
were prepared from primary CD41 T cells treated with either GST (100 ng/ml; lane 1) or GST–Tax (100 ng/ml) (lane 2), and analyzed in Western blot-
ting as described above. The arrow indicates the position of GST–Tax protein. (C) Purified Tax protein in combination with anti-CD3 antibody en-
hances infectivity of virus pseudotyped by Envs from HIV-1HXB2, HIV-189.6, or HIV-1ADA. Primary CD41 T cells were treated with either GST (20 ng/
ml) or GST–Tax protein (20 ng/ml) in the presence or absence of anti-CD3 mAb (OKT3 ascites 1:2000) for 3 d before infection. Representative results
from four independent experiments are shown. (D) Purified Tax protein in combination with anti-CD3 antibody enhances HIV-1 Env-mediated cell-to-cell
fusogenic activity. Primary CD41 T cells were treated as above, infected with vTF7-3 (expressing T7 polymerase), and mixed with BSC-1 cells infected
with vCB21R (encoding lacZ gene under the control of the T7 promoter) as well as rVV expressing the indicated HIV-1 Env. Fusion index indicates
OD570 value obtained for HIV-1 Env-mediated cell fusion relative to the background value obtained for nonfusogenic uncleaved Env-mediated cell fu-
sion. Representative results from three independent experiments are shown.
infectivity of HIV-1 in standard infection assays (data not
shown) and single-round virus replication assays; however,
these two stimuli in combination markedly enhanced in-
fectivity (Fig. 5 C). Synergy between HTLV-I Tax protein
and TCR signaling has also been reported for cytokine
production by T cells (43). These results suggest that Tax
protein produced by HTLV-I–infected cells is alone a rela-
tively weak enhancer of HIV-1 infection of adjacent cells;
however, it synergizes with other inducers of HIV-1 infec-
tion.
To determine whether Tax protein is able to influence
viral fusion/entry, we performed cell–cell fusion assays. In
this system, fusion efficiency between CD41 T cells treated
with purified Tax protein, anti-CD3 antibody, or both,
and fusion partner cells expressing HIV-1 Env is measured
by b-galactosidase activity in the cell lysates. Similar to the
single-round virus replication assays (Fig. 5 C), Tax protein
alone or anti-CD3 antibody alone modestly enhanced
HIV-1 Env-mediated fusogenic activity of CD41 T cells,
whereas the combination of both markedly enhanced fuso-
genic activity (Fig. 5 D). These effects are specific to Tax
protein in the preparation, since GST protein prepared in
the same manner had no effect when used as control and
the Tax preparation lost its activity after treatment with
anti-Tax antiserum followed by protein A/G sepharose
(data not shown). These results indicate that the effect of
Tax protein on HIV-1 infection is mediated, at least in
part, by increasing fusogenic activity.1694 HTLV-I Coinfection Enhances or Inhibits HIV-1 Infection
Induction of Tax Protein in Jurkat Cells Increases Fusogenic
Activity with HIV-1 Env. The effect of Tax protein on
HIV-1 infection was investigated in another system. Jurkat
cells JPX9 and JPX/M were stably transfected with the
wild-type and mutant form of HTLV-I Tax protein, re-
spectively, and Tax expression was induced by stimulation
with CdCl2 (Fig. 6 A). Jurkat cells express CXCR4 (a ma-
jor coreceptor for T-tropic HIV-1), but not CCR5 (a ma-
jor coreceptor for M-tropic HIV-1), as well as CD4 (a re-
ceptor for HIV-1); therefore, T-tropic Env-mediated
fusogenic activity was tested in these cells in the presence
(1Tax) or absence (2Tax) of CdCl2.
Induction of expression of wild-type Tax protein in
JPX9 cells rendered these cells more fusogenic with cells
expressing HIV-1 T-tropic IIIB Env, whereas expression
of the mutant Tax protein did not increase fusogenicity of
JPX/M cells (Fig. 6 B). The slight decrease in fusogenic ac-
tivity of JPX/M cells after CdCl2 treatment is probably due
to the toxic effect of Cd21.
CC Chemokines in Combination with anti-CD3 Enhance In-
fection and Fusogenicity with Envs from T-tropic HIV-1. The
role of CC chemokines in infection of CD41 T cells with
T-tropic HIV-1 was further investigated by using recombi-
nant CC chemokines. Although stimulation of the cells with
anti-CD3 increased replication of T-tropic HIV-1 by 10-fold,
CC chemokines alone had no or minimal effect on infec-
tivity of T-tropic HIV-1. In contrast, costimulation of the
cells with both anti-CD3 and CC chemokines further in-
creased replication of T-tropic HIV-1 up to an additional
threefold (Fig. 7 A; data not shown). We have obtained
similar results using MIP-1a or MIP-1b (data not shown).
To determine whether CC chemokines are capable of
increasing fusogenic activity of the cells with HIV-1 Envs,
CD41 T cells were either untreated or treated with anti-
CD3 alone, CC chemokines alone, or both, and then
tested for their fusogenicity with cells expressing HIV-1
Env. CC chemokines alone did not increase HIV-1 Env-
mediated fusogenic activity, whereas anti-CD3 alone did so
modestly. Combination of anti-CD3 and CC chemokines
further increased fusogenicity (Fig. 7 B). Thus, upregula-
Figure 6. Tax protein expressed in a CD41 Jurkat T cell line enhances
HIV-1 Env-mediated cell-to-cell fusion efficiency. (A) tax is inducibly
expressed in JPX9 cells (Jurkat cells stably transfected with wild-type
HTLV-I Tax protein under the control of the metallothionein promoter)
and JPX/M cells (Jurkat cells stably transfected with a nonactive mutant
form of Tax). JPX9 and JPX/M cells were treated with CdCl2 (10 mM),
and total RNA was prepared from cells before treatment (day 0) or on day
1 or 2 after treatment. Total RNA from MT-2 cells was also prepared as a
positive control. 15 mg of total RNA was analyzed in Northern blotting
using a probe specific to the tax gene (top). Ethidium bromide staining of
the gel is presented (bottom), showing the comparable levels of 18S rRNA
loaded. (B) Fusogenicity of JPX9 cells increases after induction of Tax ex-
pression. JPX9 and JPX/M cells were either untreated or treated with
CdCl2 for 2 d, and cell–cell fusion assays were performed for the measure-
ment of HIV-1 IIIB Env-mediated fusogenic activity. Fold induction in-
dicates fusogenic activity mediated by Tax (1Tax) relative to the baseline
(2Tax) fusogenic activity of each cell line. Results are means 6 SD of
four independent experiments.
Figure 7. Recombinant CC
chemokines, in combination
with anti-CD3 antibody, en-
hance replication of and fusoge-
nicity with Envs from T-tropic
HIV-1. (A) Primary CD41 T
cells were either untreated or
treated with CC chemokines
(200 ng/ml RANTES [R&D
Systems]), anti-CD3 antibody, or
both for 3 d before infection
with HIV-1NL4-3 or HIV-1ADA.
Representative results from three
independent experiments are
shown. (B) Primary CD41 T
cells were treated as in A, and in-
fected with vTF7-3 (fusion tar-
gets), and CD41 T cells stimu-
lated with anti-CD3 were
infected with vCB21R as well as
rVV expressing HIV-1NL4-3 Env
(fusion effectors). Results were
means 6 SD from three inde-
pendent experiments.1695 Moriuchi et al.
tion of T-tropic HIV-1 infection by CC chemokines is
mediated, at least in part, by enhancement of fusogenic ac-
tivity of the cells with HIV-1 Envs.
HTVL-I Virions in Combination with Anti-CD3 Enhance
HIV-1 Infection. The role of HTLV-I virions in HIV-1
infection of CD41 T cells was further investigated by using
purified HTLV-I particles. Stimulation of the cells with
purified HTLV-I particles (1 mg/ml of protein) alone mod-
estly enhanced infectivity of HIV-1 bearing either T- or
M-tropic Env in single-round virus replication assays,
whereas costimulation of the cells with both purified
HTLV-I particles and anti-CD3 enhanced the infectivity
markedly (Fig. 8). These results confirmed a previous study
demonstrating that HTLV-I virions are able to enhance
HIV-1 replication in CD41 T cells (25).
In this study we have demonstrated in several different
systems that soluble factors from HTLV-I–infected cells are
able to modulate HIV-1 infection of adjacent CD41 T cells
in a positive or negative fashion. As previously reported
(41), the CC chemokines RANTES, MIP-1a, and MIP-1b
produced by HTLV-I–transformed cells suppressed M-tropic
HIV-1 infection; however, in our studies, these chemo-
kines were also involved in upregulation of T-tropic HIV-1
replication. We have demonstrated that direct addition of
CC chemokines, in combination with anti-CD3, to CD41
T cells renders the cells more fusogenic with HIV-1 Envs.
Since CC chemokines have been demonstrated to have a
variety of effects on T cells (44–50), any of those activities
of the CC chemokines may be involved in the enhance-
ment of T-tropic HIV-1 replication. We are currently in-
vestigating cellular and molecular mechanisms of the CC
chemokine–mediated effect. We have also confirmed a
previous study showing that HTLV-I virions are able to ac-
tivate T cells and enhance T-tropic HIV-1 replication (25).
The mechanisms of Tax-mediated effects may be more
complex. HTLV-I Tax protein has been shown to upregu-
late expression of HIV-1 (8), as well as expression of vari-
ous cytokines and cytokine receptors involved in T cell ac-
tivation (for review see references 51, 52), thereby providing
favorable circumstances for HIV-1 infection. However, ex-
pression of anti-HIV CC chemokines is also induced by di-
rect addition of soluble Tax protein (Moriuchi, H., M. Mo-
riuchi, and A.S. Fauci, unpublished observations). Therefore,
the net effect of Tax protein may depend upon the balance
or accumulation of those effects. We have demonstrated
that Tax protein is able to enhance HIV-1 fusion/entry. It
is likely that Tax protein transactivates expression of cellu-
lar factors that are required for viral fusion/entry. We have
recently cloned the promoter regions for CXCR4 (53) and
CCR5 (54), and demonstrated that Tax is able to transacti-
vate these promoters (Moriuchi, H., M. Moriuchi, and A.S.
Fauci,  unpublished observations). Thus, upregulation of
coreceptor expression may be responsible, at least in part,
for the effect of Tax on HIV-1 fusion/entry.
Our present study also indicates that the effect of
HTLV-I coinfection on the pathogenesis of HIV disease is
multifactorial, and that soluble factors produced by HTLV-
I–infected cells are capable of enhancing and/or suppress-
ing HIV-1 infection of adjacent cells, depending on the
balance of effects of the factors involved and the tropism of
the virus. Although an increase in replication of T- and
dual-tropic HIV-1 is consistently seen, the balance of en-
hancing and suppressing factors determines the net effect
on M-tropic HIV-1 infection. Discrepancy among previ-
ous studies (10–12, 14–17) on the effect of HTLV-I/HIV
coinfection on HIV disease progression may reflect these
potentially dichotomous effects on M-tropic HIV-1. In this
regard, infection with HTLV-I may favor the transition
from M- to T-tropic phenotype, which is associated with
HIV disease progression (3, 57–59).
In conclusion, this study provides possible mechanisms
whereby coinfection of an individual with HIV-1 and
HTLV-I influences the course of HIV-1 infection without
necessity for actual coinfection of the same cells by the two
pathogens. Further studies are required to establish the ac-
tual effects of HTLV-I coinfection on the clinical progres-
sion of HIV infection in vivo.
Figure 8. HTLV-I virions, in
combination with anti-CD3 an-
tibody, enhance replication of
HIV-1. Primary CD41 T cells
were either untreated or treated
with HTLV-I particles (1 mg/ml
protein), anti-CD3 antibody, or
both for 3 d before infection
with NL4-3-Luc-R2E2 virus
pseudotyped by Env from HIV-
1HXB2 or HIV-1ADA. Similar re-
sults were obtained twice.
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